“Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028” Report Highlights:
- Global Bispecific Antibody Market Opportunity: > US$ 20 Billion
- Global Bispecific Antibody Market Growth Rate: 121% CAGR (2016 -2020)
- Global Bispecific Antibody Sales In 2020: >55%
- Bispecific Antibodies In Clinical Trials: More Than 400 Antibodies
- Commercially Available Bispecific Antibodies: 3 (Blincyto, Hemlibra) & Rybrevant
- Approved Bispecific Antibodies Dosage, Patent, Price, Yearly Sales, Quarterly Sales, Global and Regional Sales Insight
Following the approval of first monoclonal antibody in late 90s, therapeutic monoclonal antibodies and other antibody related products have grown to become dominant product class within the biopharmaceutical market. Today, monoclonal antibodies have been approved for a variety of diseases, ranging from those that treat patient population of orphan designation such as paroxysmal nocturnal hemoglobinuria to those treating thousands of patients for some cancers, multiple sclerosis and rheumatoid arthritis. Despite their immense clinical response, their use is restricted by their high cost, inability to cross blood brain barrier and large size.
To overcome these limitations, researchers have done extensive research and development activities in this field which have led to the development of bispecific antibody. The bispecific antibody is novel class of therapeutic antibodies which can simultaneously bind two separate and unique antigens. The dual specificity of the construct opens a wide range of opportunities for the researchers and can be exploited to target two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to target site. In addition this, the small size of bispecific antibodies not only enables it to pass through blood brain barrier but also smoothens the manufacturing process.
Currently, only two bispecific antibodies have been approved for therapeutic purpose. Blinatumomab developed by Amgen consists of 2 variable segments, one binding to B-lymphocyte antigen CD19 and the other to CD3 on T cells and is indicated for the management of acute lymphoblastic leukemia. Another, Hemlibra developed by Roche is a bispecific antibody used in the management of Haemophilia. The approval of these antibodies has greatly transformed the overall market. In short stretch of time, the bispecific antibodies have shown high penetration into the market which can be justified by their robust sales since their approval.
Bispecific antibodies used in oncology provide a higher binding specificity, which allows the immune cells to directly contact tumor cells, enhancing their cytotoxicity. In the past 10 years, the amount of research devoted to bispecific antibodies have increased significantly. As of now, several pharmaceutical companies including Roche, Amgen, Macrogenics, Janssen Pharmaceutical, and several others have invested a large amount to develop a strong clinical pipeline of bispecific drugs. The majority of these drugs are present at early stage of clinical trial, thus it is expected that the market will be flourish with several bispecific antibodies in next 3-5 years.
As report findings, it is expected that the global bispecific antibody will witness high growth rates to surpass US$ 20 Billion by 2026. The increase in prevalence of cancer and other chronic disease is projected to contribute to the growth of bispecific antibodies market during the forecast period. Moreover, increasing research collaboration for the development of robust pipeline and rising initiatives by government as well as private sectors will further propel the growth of market. Geographically, US is expected to dominate the market for next few years attributing to the presence of large pharmaceutical sector and increasing awareness among the population for novel therapies. In addition to this, Europe and Asia-Pacific will also emerge as potential market due to rising support from the government and unmet need for targeted therapies.